Efficacy Comparison of Bevacizumab Combined with Raltitrexed or Capecitabine in the Treatment of Advanced Colorectal Cancer
Objective To compare the clinical efficacy of bevacizumab combined with raltitrexed or capecitabine in the treatment of advanced colorectal cancer.Methods A total of 110 patients with advanced colorectal cancer admitted to the Cangzhou Central Hospital from February 2021 to August 2022 were selected and divided into the bevacizumab + capecitabine group and the bevacizumab + raltitrexed group by the random number table method,with 55 cases in each group.The patients in the two groups were given intravenous drip of Bevacizumab Injection,on this basis,the patients in the bevacizumab + capecitabine group were given Capecitabine Tablets orally,while the patients in the bevacizumab + raltitrexed group were given intravenous drip of Raltitrexed for Injection(another intravenous-drip access was established).Both groups were treated for six courses with three weeks as a course and followed up for six months.Results After treatment,the overall survival(OS)and progression-free survival(PFS)in the bevacizumab + capecitabine group were(12.26±2.94)months and(6.17±1.74)months respectively,which were similar to(12.57±2.15)months and(6.62±1.80)months in the bevacizumab + raltitrexed group(P>0.05).The objective response rate(ORR)and disease control rate(DCR)in the bevacizumab + raltitrexed group were 34.55%and 65.45%respectively,which were similar to 32.73%and 61.82%in the bevacizumab + capecitabine group(P>0.05).After treatment,the vascular endothelial growth factor(VEGF),basic fibroblast growth factor(bFGF),platelet-derived growth factor(PDGF)and T lymphocyte subsets(CD3+,CD4+,CD8+)levels in the two groups improved significantly(P<0.05),and those in the bevacizumab + raltitrexed group were significantly better than those in the bevacizumab + capecitabine group(P<0.05).The incidence of hand-foot syndrome and diarrhea with grade Ⅰ-Ⅱ and grade Ⅲ-Ⅳ,nausea,vomiting and peripheral neurotoxicity with grade Ⅰ-Ⅱ in the bevacizumab + raltitrexed group was significantly lower than that in the bevacizumab + capecitabine group(P<0.05).Conclusion Bevacizumab combined with raltitrexed or capecitabine in the treatment of advanced colorectal cancer had similar efficacy,while the former drug combination is more effective in improving the levels of serum angiogenic factors and T lymphocyte subsets.
bevacizumabraltitrexedcapecitabineadvanced colorectal cancerangiogenic factorT lymphocyte subsetsurvival status
万方数据
维普
